Relatlimab (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Relatlimab" in Italian language version.

Last modified: 06:04:40, 29 August 2025 (UTC)

Ref.Un. Ref.Website

Global rank Italian rank

31businesswire.com

828^th place

1,152^nd place

5^th place

6^th place

11clinicaltrials.gov

4,259^th place

3,825^th place

businesswire.com (Global: 828^th place; Italian: 1,152^nd place)

(EN) U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma, su BusinessWire, Bristol-Myers Squibb, 18 marzo 2022. URL consultato il 2 aprile 2022.

clinicaltrials.gov (Global: 4,259^th place; Italian: 3,825^th place)

(EN) An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma, su ClinicalTrials.gov. URL consultato il 2 aprile 2023.

nih.gov (Global: 5^th place; Italian: 6^th place)

dailymed.nlm.nih.gov

(EN) Opdualag- nivolumab and relatlimab-rmbw injection, su DailyMed. URL consultato il 2 aprile 2023.